Contacts

MedinCell publishes its financial results for the first semester of 2022-2023 (April – September 2022)

December 6, 2022

Revenue: €7.7 million (+89% compared to the first half of the previous year)
Operating expenses: €19.4 million (+27% compared to the first half of the previous year)
Cash consumption from operations: €10 million
Available cash: €11.7 million in cash and cash equivalent + €2.5 million in non-risky current financial assets in September 30, 2022
Post-closing: expected cash inflows of more than €29 million by the end of the first semester 2023 and revision of the investment plan

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.